ESPR Q1 2019 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q1 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$145M

Gross Profit

$99M68.2% margin

Operating Income

$87M59.8% margin

Net Income

$87M60.1% margin

EPS (Diluted)

$3.07

QoQ Revenue Growth

-21.2%

Cash Flow

Operating Cash Flow

$92M

Free Cash Flow

$92M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$236M

Total Liabilities

$61M

Stockholders' Equity

$175M

Cash & Equivalents

$175M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$145M	$0	—
Gross Profit	$99M	-$41M	+342.1%
Operating Income	$87M	-$47M	+285.4%
Net Income	$87M	-$46M	+289.4%

Revenue Segments

License For Intellectual Property Revenue

$144M99%

Ongoing Regulatory And Development Activities Revenue

$1M1%